LLC "Binnopharm Group"

LLC "Binnopharm Group" is one of Russia’s largest pharmaceutical manufacturers, established in 2020 through the unification of multiple production sites, including Synthesis, ALIUM, Binnopharm, and Biokom. The company operates across a broad spectrum of prescription and over-the-counter medications, leveraging its own active pharmaceutical substance production to enable full-cycle manufacturing for a substantial portion of its portfolio. The group emphasizes a diversified production footprint and a substantial manufacturing footprint, reflecting its status as a major player in the Russian pharmaceutical industry.

With integrated industrial sites located in several Russian regions, Binnopharm Group brings together capabilities in solid dosage forms, active pharmaceutical ingredients, and high-tech production processes. The consolidation of facilities under one corporate structure enables the company to coordinate product development, contract manufacturing, and a broad spectrum of pharmaceutical formulations including tablets, capsules, sprays, injections, and suppositories. The scale of manufacturing capacity is notable, with tens of thousands of square meters of production space and a large workforce dedicated to pharmaceutical production.

The company maintains a strong market presence in both tender-based and retail segments of the Russian pharmaceutical market. It has established export operations that reach 15 countries, underscoring its role in international supply chains and cross-border pharmaceutical trade. Binnopharm Group’s emphasis on transparency and collaborative partnerships supports its engagement with distributors, pharmaceutical networks, equipment suppliers, research institutions, and financial entities.

Operationally, the group highlights its multifaceted production platform, including major facilities in Obolensk (Moscow region), Kursk, Stavropol, and Zelenograd, each contributing to the manufacture of various dosage forms and pharmaceutical substances. Obolensk specializes in modern solid dosage form production (tablets, capsules, powders) across a sizable facility, Kursk hosts a major production site for pharmaceutical substances and medicines across multiple dosage forms, Stavropol focuses on efficient small-to-medium batch production and advanced coating technologies for tablets, and Zelenograd centers on innovative biotechnological products.

Binnopharm Group stresses a track record of collaboration with Russian and international partners to develop product portfolios, organize contract manufacturing, advance scientific research, and support the broader pharmaceutical ecosystem. Its positioning within the top tier of domestic pharmaceutical manufacturers reflects its scale, export capabilities, and ongoing investments in production capacity and technology.

The company’s growth trajectory is anchored by a combination of manufacturing scale, diversified product forms, and a strategic focus on both domestic market leadership and international supply relationships. While extensive quantitative indicators such as revenue and employment are publicly highlighted, the organization emphasizes its expansive manufacturing footprint and its status as a key contributor to Russia’s pharmaceutical landscape.